---
trial_id: 1540
discovery_date: 2022-07-29 15:03:31.662319
date: 2022-07-29 15:03:31.662319
title: "A Phase 2, double-blind, randomized, placebo-controlled study assessing efficacy and safety of SAR441344, a CD40L-antagonist monoclonal antibody, in participants with relapsing multiple sclerosis"
summary: |
  <p>EudraCT Number: 2020-004785-19<br />Sponsor Protocol Number: ACT16877<br />Sponsor Name: Sanofi-Aventis Recherche et Développement<br />Start Date: 2021-06-01<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004785-19/CZ">CZ</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004785-19/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004785-19/BG">BG</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004785-19'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2020-004785-19<br />Sponsor Protocol Number: ACT16877<br />Sponsor Name: Sanofi-Aventis Recherche et Développement<br />Start Date: 2021-06-01<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004785-19/CZ">CZ</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004785-19/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004785-19/BG">BG</a> (Ongoing)</p>